Biogen Inc Dossier - Source-backed chat

Biogen Inc

BIIBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.44

Intrinsic Value $202.99median of 6 methods · middle span $177-$324based on filings through 31 Mar 2026

Market Price $222.82Price as of 1 Oct 2026

Near fair valueIntrinsic value is 9% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $32.9B

Enterprise Value $35.8B

Shares Outstanding 148.9M diluted

Moat Rating None

Next Earnings Date28 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Biogen has strengthened its growth platform through the U.S. availability of LEQEMBI IQLIK for initiation and maintenance therapy, completed acquisitions of Apellis and RayThera, and encouraging clinical progress for diranersen and litifilimab. These developments improve portfolio breadth beyond the company's mature franchises, but the investment case still depends on launch execution, acquisition integration, and successful completion of pivotal trials.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets32 analysts · as of 18 Aug 2026

Low · most bearish analyst$165.00

Mean target$237.59

High · most bullish analyst$300.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$165.0024%

LEQEMBI IQLIK fails to produce durable adoption gains, integration of recently acquired portfolios distracts management or leads to program attrition, and pivotal development of litifilimab, diranersen, or other pipeline assets is delayed or produces weaker results than earlier studies suggested.

Base CaseCentral scenario

$237.5956%

Matches the consensus mean

LEQEMBI adoption improves gradually following availability of at-home initiation dosing, the acquired Apellis and RayThera portfolios broaden the pipeline, and the principal late-stage programs remain on schedule, including the announced 2027 litifilimab readout. Execution and clinical uncertainty prevent a stronger conclusion.

Bull CaseUpside scenario

$300.0020%

LEQEMBI IQLIK materially lowers treatment-administration barriers, Apellis and RayThera integrate without significant program disruption, and positive diranersen and litifilimab evidence translates into successful late-stage development. This would establish multiple independent growth drivers across Alzheimer's disease, rare disease, nephrology, and immunology.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

LEQEMBI IQLIK became available in the United States for at-home initiation as well as maintenance therapy, potentially reducing dependence on infusion infrastructure.
Completed acquisitions of Apellis and RayThera broaden Biogen's exposure to complement-driven diseases, nephrology, rare disease, and small-molecule immunology.
Diranersen is planned to advance into confirmatory Phase 3 development after positive Phase 2 CELIA findings, while litifilimab produced a second positive Phase 2 result in cutaneous lupus.

Key Investment Risks

LEQEMBI's commercial trajectory remains dependent on patient identification, treatment access, safety monitoring, and conversion of formulation convenience into sustained utilization.
The acquisitions of Apellis and RayThera create integration and portfolio-prioritization risk shortly after closing.
Diranersen and litifilimab remain investigational, and encouraging Phase 2 evidence may not be replicated in confirmatory or pivotal trials.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.